Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced the composition of its board of directors, which consists of 12 members, including executive, non-executive, independent non-executive, and employee directors. The announcement also detailed the membership of five specialized committees, highlighting the roles and functions of each board member. This update on the board’s structure could influence the company’s strategic direction and governance, impacting stakeholders’ interests.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. It focuses on the development, manufacture, and sale of pharmaceutical products, medical devices, and healthcare services.
Average Trading Volume: 6,907,858
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.52B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.